THIS PRODUCT IS NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC

Kind Aura™

Aura is a full spectrum oil with high levels of THC.

Extracted from the sativa cultivar, Island Honey, each 1ml 510cartridge contains 70% (w/w) THC (delta-9-tetrahydrocannabinol) and <1%(w/w) CBD (cannabidiol).

Product Introduction

Kind Aura™ is a full spectrum oil extracted from a sativa cultivar with high concentrations of THC (delta-9-tetrahydrocannabinol)and low levels of CBD (cannabidiol). All medicinal cannabis products that contain THC are psychoactive and may lead to temporary impairment.

Aura is available in a 1ml 510 cartridge and is designed for inhalation with a compatible 510 vaporisation device. It can be taken on a metered dosage schedule or as needed (PRN) as determined by prescribers. We recommend patients work closely with their doctor as appropriate dosing schedules are highly individual.

Product Details

Product Size
1ml Cannabis Flower Extract

CBD (mg/g)
<1% w/w

TGA Classification
Schedule 8 / Category 5

THC (mg/g)
70% w/w

Kind Product Spectrum

Terpene Profile
Subject to batch-by-batch variation

Key Information

Cannabinoid Content per 3-Second Draw

Based on an average 510 battery in market, Aura vaporises at a rate of approximately 3.5mg THC per 3-second inhale.

Warning: Patients are advised not to drive or operate complex machinery within 24 hours after consuming medication containing THC.

Storage: Store away from direct sunlight in a cool, dry place. Place in a secure location out of the reach of children. Keep 510 cartridge attached to vaporisation device once installed. If removed from the battery, keep the cartridge upright with the rubber stoppers attached.

Indications

The TGA has approved SAS applications including, but not limited to, the following:

  • Chemotherapy induced nausea and vomiting (CINV)
  • Refractory paediatric epilepsy
  • Neuropathic and chronic pain
  • Palliative care
  • Cancer pain
  • Anxiety
  • Insomnia & Sleep Disorders
  • Post Traumatic Stress Disorder (PTSD)
  • Spasticity from neurological conditions (e.g. Multiple Sclerosis)
  • Anorexia and wasting associated with chronic illness (e.g. cancer)

Note: The TGA does not endorse medicinal cannabis as a treatment for any condition and does not vouch for the safety or efficacy of medicinal cannabis treatments. It is entirely for the prescribing doctor to determine whether unregistered medicinal cannabis treatments are appropriate for their patient.

Dosing & Titration

Titration is the process of gradually increasing a dose until the desired result is achieved. In line with TGA guidance, we recommend following the “start low, go slow” approach whereby patients start with a low dose and slowly increase until the optimal therapeutic benefit is achieved.

Dosing is highly individual, so patients and doctors should work together to determine the optimal dosing schedule where the medical benefit is maximised within the individual patient’s context.

However, below is an example of a titration schedule:

Accurate dosing and titration of medicinal cannabis extracts can be challenging due to several factors. These include inconsistency in the amount of medicine administered, variance in cannabinoid profiles, discrepancies in temperature during vaporisation, and length and depth of breath when inhaled.

For reliable and repeatable dosing of medicinal cannabis, we recommend patients aim to replicate consistently the conditions in which they self-administer medicinal cannabis.

When starting the titration process, patients and doctors should maintain a consistent dosing schedule and adjust dose timing if needed. New medicinal cannabis patients should wait up to 30 minutes between their initial dose before their next inhalation.2

This mindset towards repeatable control of dosing should extend to determining the specific milligram value of active cannabinoids within cannabis flower extract.

Administration Through Inhalation

The use of a vaporiser to inhale medicinal cannabis is one of the most efficient administration methods for patients. Inhalation offers a rapid onset time, typically providing relief in 5 to 10 minutes, with an expected duration of 2 to 4 hours. This is significantly faster than oral and sublingual ingestion which have an onset period of 1 to 3 hours.3

There are several important factors to understand when inhaling medicinal cannabis. Kind Medical Full Spectrum oil products cannot be combusted and must only be used in conjunction with a 510 compatible vaporisation device.

Patients should instead opt to use a TGA-approved vaporiser to heat the dried medicinal cannabis flower below the point of combustion to create smoke-free vapour.

Patients should also be aware that temperature settings with vaporisers will impact their medicinal cannabis. Within the dried cannabis flower, each cannabinoid, terpenoid and flavonoid contains a different boiling point. It should be noted that there are three general temperature bands:

510 vaporisers may not explicitly state temperature bands, so patients are advised to refer to the manufacturer’s guidance to understand temperatures in their device.

Contraindications

  • Patients with cardio-pulmonary disease (consult with your doctor).
  • Women who are pregnant, breastfeeding or are planning on becoming pregnant.
  • Patients with a familial history of schizophrenia.
  • Patients with a diagnosed history of psychosis and/or active mood disorders.
  • Children or adolescents under 18 years of age.

First-Time Side Effects

There are more common side effects that are associated with taking medicinal cannabis products for the first time or from increasing usual dosing and may be of a mild and transient nature:

  • Drowsiness
  • Anxiety
  • Coughing or phlegm
  • Confusion or problems concentrating
  • Increased heart rate or palpitations
  • Euphoria or other cognitive effects
  • Occasional or brief paranoid thoughts
  • Nausea
  • Dry mouth
  • Blurred vision

If you experience any of the above side effects for a prolonged period of time (i.e. greater than 24 hours) or if severe, immediately stop taking Kind Aura™ and speak with your doctor, pharmacist or seek immediate medical attention.

This does not serve as a complete list of potential adverse effects. If you experience any unexpected severe adverse effects not listed, stop using the product immediately and contact your doctor or pharmacist.

Side Effects

Like other medicines, Kind Aura™ may produce unwanted side effects in some people. With all medicinal cannabis products there are potential adverse effects that may affect only some people.

Rare side effects that warrant immediate cessation of Aura are:

  • Hallucinations (auditory / visual)
  • Paranoia
  • Difficulty Breathing
  • Seizures or convulsions
  • Depression or suicidal thoughts
  • Fainting, lightheadedness and dizziness associated with low blood-pressure

Should you experience any or several of the above side effects, immediately stop taking Aura and speak to your doctor / pharmacist or go to a hospital.

Reporting Adverse Events

If you experience any adverse events, including listed rare side effects or common side effects for a prolonged period, please contact your doctor or pharmacist immediately. This also includes any other severe side effects not listed on this page. Reporting adverse effects assists in providing more information on the safety of this product.

Tel: 1 800 KIND HI
(1800 546 344)
Email: hi@kind.com.au

Altum Oceania Pty Ltd trading as Kind MedicalTM

PDF Version

If you have any problems reading this page or require a PDF copy for print, you may find one available for download here:

Download PDF